Pharma Industry News

Amgen and Kyowa Kirin agree to jointly develop eczema med

KHK4083 is an anti-OX40, fully human monoclonal antibody in development for the treatment of atopic dermatitisOriginal Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]